Icahn School Of Medicine At Mount Sinai
Date of Award
Crohn's Disease, Therapeutics
Term of Grant
Study to Evaluate Safety and Tolerability of Oral BFAHF-2 in Pediatric Subjects with Mild-to-Moderate Crohn's Disease
There is a lack of maintenance therapies for children with mild-to-moderate CD since many of the medications used to treat CD, including steroids, immunomodulators and biological therapies are geared towards treating moderate-to-severe disease, and present serious side effects in the pediatric patient population. Thus, there is a need for new, safe medications for treating children with mild-to-moderate CD. If successful, this proposal will establish safety and efficacy of BFAHF-2 in a small cohort, paving the way for a larger scale clinical trial.